The decree of the president of the United States, Donald Trump, on the prices of medicines threatens the investment of 50,000 million dollars planned by Roche in the United States, the company said Wednesday.
Trump’s order, signed on Monday, urges laboratories to lower the price of brand medications to align them with those of other rich countries. Legal analysts and experts say that politics would be difficult to implement.
“In the event that the decree enters into force, Roche’s capacity to finance the important investments previously announced in the United States will be questioned,” the company said in a statement.
You may be interested: Tariff truce awakens Halloween requests in China
Roche said he does not expect the decree to affect his business in 2025
Roche said he does not expect the decree to affect his business in 2025, while indicating that he will continue working with the Trump government and Congress.
Roche announced in April that it will invest 50,000 million dollars in the United States in the next five years, creating more than 12,000 jobs.
The company is one of several medication manufacturers, including Eli Lilly, Johnson & Johnson and Novartis, who have announced large -scale investments in the United States in response to Trump’s impulse to pharmaceutical manufacturing in the country.
With Reuters information.
Follow us on Google News to always keep you informed
